Talha Badar: A brief overview on MLL gene re-arranged AL in this thread
Talha Badar, Hematologist/Oncologist at Mayo Clinic, shared a thread on X/Twitter:
“Weekend review: MLL- rearrange acute leukaemia (AL). Recently there has been a lot of interest in the management of MLL-rearranged acute leukemia, courtesy development of novel Menin inhibitors. A brief overview on MLL gene re-arranged AL in this thread.
Rearrangements of the histone lysine[K]-MethylTransferase 2A gene (KMT2A) gene on chromosome 11q23, formerly known as mixed-lineage leukemia (MLL) gene, are found in10% of cases of AL. Common translocated genes are AFF1 (t [4,11]), MLLT3(t[9,11] [p2,p23]), and MLLT1 (t[11,19] [q23;p13.3]) Other less common are AF10 [t [10,11]], ELL [t [11, 19] (q23,p13.1)], and AF6 [t(6,11).
Risk stratification as per ELN 2022:
t(9;11) (p21.3;q23.3)/MLLT3::KMT2A intermediate risk t(v;11q23.3)/KMT2A-rearranged adverse risk.
Common clinical presentation:
Hyperleukocytosis Hepatosplenomegaly and lymphadenopathy commonly seen. High incidence of CNS involvement Relative high incidence of Leukemia Cutis Associated with therapy related leukemia (topoisomerase II inhibitor with short latency).
Drug resistance: In ALL, associated with resistance to steroids/peg asparaginase. Sensitive to cytarabine and another nucleoside analogue.
Common somatic co-mutation (> 5%): RAS pathway (NRAS or KRAS), found in 22% to 45%. Others in order of occurrence are FLT3, PTPN11, TP53, CEBPA, DNMT3A.
Novel therapeutic targets for MLL gene leukemia: Menin inhibitors, EZH inhibitors, HDAC inhibitors, DOT1L etc. Most advanced among them are Menin inhibitors.: At least 5 different menin inhibitors are being developed, including SNDX-5613 (Revumenib), KO-539 (Zeftomenib), JNJ-75276617, BMF-219, DS-1594a.
Allogeneic stem cell transplantation: Favorable outcome with allo-HCT have been reported in several retrospective/registry analysis.
CAR T-cell therapy for MLL gene rearranged acute leukemia: In small sub-group of patients responses in MLL-r-ALL were encouraging. Challenges:
- Loss of CD19 antigen, commonly seen with t(4;11) sub-type (post Blinatumomab)
- Lineage switch at relapse have been observed (especially postallo-HCT).
Several targets apart from CD19 have been evaluated including CD22, CD19/CD133.”
Link to Powerpoint Presentation.
Source: Talha Badar/X
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023